文献速递肿瘤 PET/CT骨显像与常规 SPECT

[18F]PSMA-1007高摄取非特异性骨病灶的临床非显著性:一项回顾性评估

Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation.
PubMed 文献 · Eur J Nucl Med Mol Imaging · 2021-06-16

该回顾性研究纳入214例前列腺癌男性患者,评估[18F]PSMA-1007 PET/CT中高摄取非特异性骨病灶(NSBL)的临床结局。NSBL与无骨病灶患者在PSA、Gleason评分和摄取时间上无显著差异;SUVmax≥7.2可最佳区分NSBL与骨转移(Youden指数最大化)。

要点

  • [18F]PSMA-1007高摄取NSBL在中位15.8个月随访中极少为前列腺癌骨转移。
  • NSBL患者与无骨病灶患者的血清PSA、Gleason评分及摄取时间无显著差异。
  • SUVmax≥7.2为区分NSBL与明确骨转移的最佳阈值,SUVmax<7.2可归类为可能良性。

核心结论

  • [18F]PSMA-1007高摄取NSBL很少代表前列腺癌骨转移,在无其他明确转移灶时SUVmax<7.2可归类为可能良性。

研究设计与样本

  • 回顾性审计214例前列腺癌男性患者,按既定标准评估[18F]PSMA-1007高摄取NSBL的临床结局,并与无骨病灶患者比较PSA、Gleason评分和摄取时间,采用ROC曲线分析SUVmax阈值。

主要发现

  • NSBL患者与无[18F]PSMA-1007高摄取骨病灶患者的血清PSA、Gleason评分和摄取时间无统计学显著差异。
  • 所有随访充分的NSBL的SUVmax≤11.1;最高SUVmax可区分NSBL与明确前列腺癌骨转移,SUVmax≥7.2使Youden指数最大化。

关键数值与推荐

  • NSBL定义为CT上无典型形态学对应的轻至中度局灶性骨摄取。
  • SUVmax<7.2的NSBL可归类为可能良性;SUVmax 7.2-11.1可归类为不确定或转移,需结合患者临床危险因素、扫描表现和潜在管理影响进行解读。

临床怎么用

  • 对于[18F]PSMA-1007 PET/CT发现的NSBL,若无其他明确转移灶且SUVmax<7.2,可判为可能良性。
  • SUVmax在7.2-11.1的NSBL应结合临床危险因素、扫描表现和管理影响综合判读为不确定或转移。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: [18F]PSMA-1007 offers advantages of low urinary tracer excretion and theoretical improved spatial resolution for imaging prostate cancer. However, non-specific bone lesions (NSBLs), defined as mild to moderate focal bone uptake without a typical morphological correlate on CT, are a common finding on [18F]PSMA-1007 PET/CT. The purpose of this study was to investigate the clinical outcomes of patients with [18F]PSMA-1007 avid NSBLs, to determine whether patients with NSBLs represent a higher risk clinical cohort, and to determine whether SUVmax can be used as a classifier of bone metastasis. METHODS: A retrospective audit of 214 men with prostate cancer was performed to investigate the clinical outcomes of [18F]PSMA-1007 avid NSBLs according to defined criteria. We also compared the serum PSA, Gleason score, and uptake time of patients with [18F]PSMA-1007 avid NSBLs to patients without [18F]PSMA-1007 avid bone lesions. Finally, we analysed an SUVmax threshold to identify bone metastases using ROC curve analysis. RESULTS: Ninety-four of 214 patients (43.9%) demonstrated at least one NSBL. No [18F]PSMA-1007 avid NSBLs met criteria for a likely malignant or definitely malignant lesion after a median 15.8-month follow-up interval (11.9% definitely benign, 50.3% likely benign, and 37.7% equivocal). There were no statistically significant differences in serum PSA, Gleason score, and uptake time between patients with [18F]PSMA-1007 avid NSBLs and those without [18F]PSMA-1007 avid bone lesions. All NSBLs with adequate follow-up had SUVmax ≤ 11.1. The value of the highest SUVmax distinguished between NSBLs and definite prostate cancer bone metastases, whereby an SUVmax threshold of ≥ 7.2 maximized the Youden's index. CONCLUSION: [18F]PSMA-1007 avid NSBLs rarely represent prostate cancer bone metastases. When identified in the absence of definite metastatic disease elsewhere, it is appropriate to classify those with SUVmax < 7.2 as likely benign. NSBLs with SUVmax 7.2-11.1 may be classified as equivocal or metastatic, with patient clinical risk factors, scan appearance, and potential management implications used to guide interpretation.

来源:Eur J Nucl Med Mol Imaging,查看原文。版权归原作者所有。

引用

  1. Arnfield EG, Thomas PA, Roberts MJ, et al. Clinical insignificance of [18F]PSMA-1007 avid non-specific bone lesions: a retrospective evaluation. Eur J Nucl Med Mol Imaging. 2021. PMID: 34136957. doi:10.1007/s00259-021-05456-3

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。